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E1B 55kx plays a central role in DNA double-strand break repair by non-homologous end
joining (NHEJ). During adenovirus infection, NHEJ is inhibited by viral proteins E4 34k and E1B 55k, which
redirect the Cul5/Rbx1/Elongin BC ubiquitin E3 ligase to polyubiquitinate and promote degradation of ligase
IV. In cells infected with E1B 55k-deﬁcient adenovirus, ligase IV could not be found in XRCC4-containing
complexes and was observed in a novel ligase IV/E4 34k/Cul5/Elongin BC complex. These observations
suggest that dissociation of the ligase IV/XRCC4 complex occurs at an early stage in E4 34k-mediated
degradation of ligase IV and indicate a role for E4 34k in dissociation of the ligase IV/XRCCC4 complex.
Expression of E4 34k alone was not sufﬁcient to dissociate the ligase IV/XRCC4 complex, which indicates a
requirement for an additional, as yet unidentiﬁed, factor in E1B 55k-independent dissociation of the ligase
IV/XRCC4 complex.
© 2008 Published by Elsevier Inc.Introduction
DNA damage occurs in all living cells either as a result of
environmental insults or normal metabolic processes and presents a
major threat to the integrity of the genome. In particular, DNA double-
strand breaks (DSBs) can lead to genetic rearrangements that promote
tumor formation. Eukaryotic cells repair DSBs by two mechanisms:
homologous recombination, which is used for repair of DSBs that
occur during late-S or G2 phases of the cell cycle, and non-
homologous end joining (NHEJ), which is used during G0 and G1
phases of the cell cycle (Lieber et al. 2004, Sonoda et al. 2006,
Weterings and Chen 2008). In addition to spontaneous DSBs, somatic
cell recombination processes required for immunoglobulin (Ig)
production and diversiﬁcation are initiated by DSBs that are repaired
by NHEJ (Lieber et al. 2004, Weterings and Chen 2008). Because of the
large proportion of non-cycling cells in multicellular organisms and
the added role of DSBs in Ig production, the majority of DSBs in
humans are repaired by NHEJ (Lieber et al. 2004, Sonoda et al. 2006).
The repair of the DSBs by NHEJ involves recognition of DSBs,
localization of repair enzymes to the DSB, processing of the DNA ends
to yield ligatable termini, and ligation to reseal the break. In
mammalian cells, DSB recognition requires phosphorylation of
histone H2AX and processing of DNA ends may involve one of several
factors, which include aprataxin and polynucleotide kinase (Chappelllsevier Inc.et al. 2002, Koch et al. 2004, Ahel et al. 2006). Mammalian NHEJ also
requires the heterotrimeric DNA-dependent protein kinase (DNA-PK),
a nuclear serine/threonine protein kinase belonging to the phospha-
tidylinositol 3-related protein kinase (PI3K) family (Smith and Jackson
1999, Weterings and Chen 2008). This heterotrimeric kinase consists
of a 460 kDa catalytic subunit (DNA-PKcs) and a heterodimeric DNA
binding subunit (Ku) (Smith and Jackson 1999). Ku is thought to be
involved in the recognition of DSBs based on its abundance in nuclei
and its afﬁnity for DNA ends (Smith and Jackson 1999, Weterings and
Chen 2008). In mice, disruption of genes encoding DNA-PKcs or either
of the Ku subunits results in a spectrum of DSB repair and Ig-
production defects (Smith and Jackson 1999, Weterings and Chen
2008).
In mammalian NHEJ, the ligation event is catalyzed by DNA ligase
IV, which forms a complex with the DNA-binding proteins XRCC4 and
XLF (Bryans et al. 1999, Ahnesorg et al. 2006, Buck et al. 2006, Sonoda
et al. 2006, Weterings and Chen 2008). XRCC4 makes direct contact
with ligase IV and XLF, stimulates ligase IV activity and is essential for
ligase IV stability (Critchlow et al. 1997, Grawunder et al. 1998,
Ahnesorg et al. 2006, Buck et al. 2006, Sonoda et al. 2006, Weterings
and Chen 2008). Structural studies have shown that both XRCC4 and
XLF form homodimers with remarkable similarity in overall fold
(Junop et al. 2000, Andres et al. 2007, Li et al. 2007). Direct-binding
and structural studies paint a picture of a complex composed of 1
ligase IV: 2 XRCC4: 2 XLF that is held together through strong, direct
ligase IV/XRCC4 and XRCC4/XLF interactions with weaker, possibly
indirect, ligase IV/XLF contacts (Deshpande and Wilson 2007).
Fig. 1. E1B 55k-independent loss of ligase IV interaction with DNA-PKcs. (A) HeLa cells
were Mock, Ad5 or Ad5-mutant (H5dl1013, H5dl1015, H5dl1016, H5dl1004, H5dl1014,
H5pm1020 or H5dl110) infected and lysed in NP40 lysis buffer 20 h post-infection.
200 μg of the total extracts were subjected to immunoprecipitation (IP) with anti-DNA-
PKcs antibodies. DNA-PKcs-containing complexes were recovered, resolved by SDS-
PAGE, Western transferred and probed for Ligase IV and XRCC4. I, 15% of input lysate; IP,
immunoprecipitation using anti-DNA-PKcs antibodies; C, control IP.
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therefore radiation-sensitive and unable to carry out Ig-gene
rearrangement by V(D)J recombination (Barnes et al. 1998, Frank et
al. 1998, Lieber et al. 2004, Buck et al. 2006, Weterings and Chen
2008). In mice, disruption of ligase IV or XRCC4 results in embryonic
lethality (Barnes et al. 1998, Frank et al. 1998, Weterings and Chen
2008). The severe phenotype associated with ligase IV or XRCC4 gene
ablation likely reﬂects the central role of the ligase IV complex in
mammalian NHEJ. Interaction between the DNA-PK and ligase IV/
XRCC4/XLF complexes has been observed (McElhinny et al. 2000, Hsu
et al. 2002, Costantini et al. 2007, Yano et al. 2008). Previous reports
have described ligase IV/Ku and XRCC4/DNA-PKcs interactions, which
are believed to be important in coordinating the efforts of these two
large multi-protein complexes (Hsu et al. 2002, Costantini et al. 2007).
During infection of human cells with adenovirus, replication of the
linear dsDNA adenovirus genome and the presence of adenovirus-
genome termini can activate the host cell DSB repair response
(Weitzman and Ornelles 2005). Unperturbed, this response can result
in adenovirus genome concatamer formation and inhibits productive
lytic infection. Adenovirus genome concatenation is an NHEJ-
dependent process that requires DNA-PK, ligase IV and the Mre11
protein (Boyer et al. 1999, Stracker et al. 2002, Weitzman and Ornelles
2005). To prevent genome concatenation, human adenovirus type 5
(Ad5) encodes early proteins that speciﬁcally target ligase IV for
polyubiquitination and proteasome-mediated degradation (Baker et
al. 2007). This process requires viral proteins encoded by early region
1B (E1B 55k) and early region 4 (E4) open reading frame 6 gene
product (E4orf6, E4 34k), which also target Mre11 and p53 to
effectively disable DNA damage sensing, DSB repair and apoptosis
(Carson et al. 2003, Berk 2005). To further prevent genome
concatenation, the E4 open reading frame 3 gene product (E4orf3,
E4 11k) causes mis-localization of the nuclear Mre11 protein to
cytoplasmic aggresomes, which prevents Mre11 from acting on the
newly replicated Ad5 genomes (Araujo et al. 2005).
Study of the molecular mechanism that underlies adenovirus-
directed protein degradation has shown that the Ad5 E1B 55k and E4
34k proteins form a complex that re-directs a host ubiquitin E3 ligase
to polyubiquitinate host factors (Querido et al. 2001, Blanchette et al.
2004, Cheng et al. 2007). This system has been most thoroughly
studied in the context of p53 degradation during Ad5 infection. The
Cul5/Rbx1/Elongin BC ubiquitin E3 ligase is bound by E4 34k through
direct contact with Cul5 and the Elongin BC complex to form an Ad5-
speciﬁc E4 34k ubiquitin E3 ligase (Blanchette et al. 2004, Cheng et al.
2007). It is thought that efﬁcient selection and delivery of p53 to the
E4 34k ubiquitin E3 ligase is mediated by E1B 55k, which binds to E4
34k and delivers p53 only after assembly of the Ad5-speciﬁc E4 34k/
Cul5/Rbx1/Elongin BC ubiquitin E3 ligase (Blanchette et al. 2004).
Cul5-dependent polyubiquitination of p53 has been observed, and
because polyubiquitination acts as a general signal for proteasome-
mediated degradation, viral redirection of the Cul5/Rbx1/Elongin BC
ubiquitin E3 ligase results in effective elimination of targeted host
proteins (Querido et al. 2001, Blanchette et al. 2004, Cheng et al. 2007).
Ad5-directed degradation of ligase IV requires the same factors
necessary for degradation of p53 and is thought to proceed by the
same mechanism. Interestingly, while ligase IV is known to form a
stable complex with the XRCC4 and XLF proteins, Ad5-directed
degradation of ligase IV does not appear to affect XRCC4 or XLF protein
levels (Baker et al. 2007). This observation suggests that the ligase IV/
XRCC4/XLF complex is dissociated at some stage during the virus-
speciﬁc pathway that targets ligase IV for degradation. Previous
observation of an E1B 55k/ligase IV complex suggests that ligase IV,
like p53, is speciﬁcally recognized by E1B 55k and then delivered to
the E4 34k/Cul5/Rbx1/Elongin BC ubiquitin E3 ligase.
In this communication, we show that in the absence of E1B 55k,
ligase IV is bound by E4 34k to form a complex that contains Elongins
B and C, but does not contain XRCC4. Our ﬁndings show that ligase IV,like p53, is recognized by both E1B 55k and E4 34k and indicate an
important role for E4 34k in dissociation of the ligase IV/XRCC4
complex. Because expression of E4 34k alone was not sufﬁcient to
cause dissociation of the ligase IV/XRCC4 complex, our observations
suggest the possibility that an additional factor is required for E4 34k-
dependent, E1B 55k-independent dissociation of the ligase IV/XRCC4
complex.
Results
Infection with Ad5 deletion mutants reveals that viral expression of E4
34k compromises the DNA-PKcs/ligase IV interaction in an E1B
55k-independent fashion
While DNA-PK has been shown to functionally and physically
interact with the ligase IV/XRCC4 complex (Hsu et al. 2002), during
Ad5 infection, DNA-PK and XRCC4 appear to be unaffected, while
ligase IV is degraded (Baker et al. 2007). Because E4 34k participates in
ligase IV degradation and co-immunoprecipitates (co-IP) with DNA-
PKcs (Boyer et al. 1999, Baker et al. 2007), we wanted to examine the
effect of Ad5 infection on the interactions between the DNA-PK and
ligase IV/XRCC4 complexes. To address this question we prepared
lysates from cells infected with wild type or deletion mutants of Ad5,
used immunoprecipitation (IP) to isolate DNA-PKcs-containing pro-
tein complexes and then used Western blot analysis to determine if
XRCC4 and ligase IV were associated with DNA-PKcs. In extracts
prepared from mock-infected cells, we were able to detect both ligase
IV and XRCC4 in the input lysate and in the DNA-PKcs co-IP (Fig. 1,
top). We interpret these data as the result of direct protein–protein
interactions between XRCC4 and DNA-PKcs (Hsu et al. 2002) and
between XRCC4 and ligase IV (Critchlow et al. 1997, Grawunder et al.
1998), which result in an indirect (i.e. through XRCC4) interaction
between ligase IV and DNA-PKcs (Fig. 1). In extracts prepared from
cells infected with wild type Ad5, it is worth noting that ligase IV was
absent and the co-IP between XRCC4 and DNA-PKcs was still
observable (Fig. 1, top). Similar results were obtained with extracts
prepared from cells infected with H5dl1013 and H5pm1020, which
Table 1
Genotypes of E4 and E1B mutants used in this study. +, intact open reading frame; −,
disrupted open reading frame
Mutant E4orf1 E4orf2 E4orf3
(E4 11k)
E4orf4 E4orf6
(E4 34k)
E4orf3/
4
E4orf6/
7
E1B
55k
Ad5 + + + + + + + +
H5dl1004 + − − − − − − +
H5dl1011 − − − − − − − +
H5dl1013 − − − + + − − +
H5dl1014 − − − + − − − +
H5dl1015 − − + + − + − +
H5dl1016 − − − + + − − −
H5pm1020 + + + − + + + +
H5dl110 + + + + + + + −
All mutations are deletions except for the ATG mutation that inactivates ORF 4 in
H5pm1020 and an 8 bp insertion that interrupts ORF 7 in H5dl1013.
Fig. 2. Loss of ligase IV/XRCC4 interaction in lysates from H5dl1016-infected cells. HeLa
cells were Mock-, Ad5- or H5dl1016-infected and lysates were prepared 20 h post-
infection. (A) Ligase IV and XRCC4 failed to co-IP from H5dl1016-infected cell lysate.
Cells were lysed in NP40 lysis buffer and 200 μg of the total extracts were subject to IP
with anti-XRCC4 antibodies. XRCC4-containing complexes were recovered, resolved by
SDS-PAGE, Western transferred and probed for Ligase IV and XRCC4. I, 15% of input
lysate; IP, immunoprecipitation using anti-XRCC4 antibodies, C, control IP. (B) DNA
binding by XRCC4 and ligase IV is inhibited in extracts from H5dl1016-infected cells.
Mini-WCE was prepared and 50 μg of mWCE was used for DNA-cellulose collection of
DNA-binding proteins. I, 15% of the input extract; B, collected DNA-binding proteins; U,
the extract following removal of DNA-binding proteins (unbound). Fractions were
resolved by SDS-PAGE, Western transferred and probed for Ligase IV or XRCC4.
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of ligase IV was not observed in lysates prepared from cells infected
with viruses that did not express E4 34k, and we were able to observe
the interaction between the DNA-PK and ligase IV/XRCC4 complexes
(Fig. 1 H5dl1004, H5dl1014 with H5dl1015).
Ad5-deletion mutants H5dl1016 and H5dl110 do not express E1B
55k (Table 1) and are, therefore, impaired for targeted degradation of
ligase IV. In lysates prepared fromH5dl1016- or H5dl110-infected cells,
we detected ligase IV and XRCC4 in the input lysate, although the
amount of ligase IV appeared to be slightly reduced when compared
with extracts prepared from mock-infected cells. Interestingly,
although the ligase IV polypeptide was present in lysates prepared
fromH5dl1016- or H5dl110-infected cells and wewere able to observe
the direct interaction between XRCC4 and DNA-PKcs, in neither lysate
were we able to observe the co-IP between ligase IV and DNA-PKcs
(Fig. 1, center). These data suggest that while the ligase IV and XRCC4
polypeptides remain intact in H5dl1016- or H5dl110-infected cells, the
direct interaction between these NHEJ factors has been compromised.
Although E4 11k is known to act on host DSB repair factors,
expression of E4 11k had no effect on ligase IV, or on its indirect
interaction with DNA-PKcs (Fig. 1, compare H5dl1014 with H5dl1015).
Similarly, disruption of the indirect DNA-PKcs/ligase IV interactionwas
independent of E4orf1-3, E4orf3/4 and E4orf6/7 expression (Fig. 1A,
compare H5dl110 with H5dl1016). Western blots of lysates prepared
from cells infected with the adenoviruses used did not show high
molecular weight forms of ligase IV, which would be consistent with
ubiquitination. Taken together, the data presented in Fig. 1 shows that
viral expression of E4 34k in the absence of E1B 55k can abrogate the
co-IP between DNA-PKcs and ligase IV. These data suggest that
important functional interaction between XRCC4 and ligase IV had
been compromised by an E1B 55k-independent mechanism.
E1B 55k-independent disruption of the ligase IV/XRCC4 direct interaction
To conﬁrm that loss of an observable DNA-PKcs/ligase IV co-IP
reﬂected loss of the stable ligase IV/XRCC4 direct interaction, we
compared XRCC4 IPs using extracts prepared from mock- and Ad5-
infected cells with extracts prepared from cells infected with the E1B
55k-, E4 11k-deﬁcient adenovirus H5dl1016. As shown in Fig. 2A, in
extracts prepared frommock-infected cells, both the XRCC4 and ligase
IV polypeptides were detected in the input lysate and in the XRCC4 IP.
In Ad5-infected cell lysates, degradation of ligase IV precluded
observation of ligase IV in the lysate or the XRCC4 IP. In extracts
prepared from H5dl1016-infected cells we again found that the
amount of ligase IV detected in the input lysate was slightly reduced
relative to the amount observed in extracts prepared from mock-
infected cells. Signiﬁcantly, in extracts prepared from H5dl1016-
infected cells, ligase IV did not co-IPwith XRCC4.Western blot analysis
conﬁrmed the presence of E1B 55k in extracts prepared from Ad5-infected cells, but not in lysates of mock- or H5dl1016-infected cells
(data not shown). These data show that, in the absence of E1B 55k, the
strong, functionally important direct interaction between ligase IV
and XRCC4 had, in fact, been compromised.
DNA binding by the ligase IV/XRCC4 complex has previously been
described (Marchetti et al. 2006) and this biochemical activity is
thought to be important to the biology of this complex. To determine
whether the loss of ligase IV/XRCC4 direct interaction affected the
dsDNA binding by XRCC4 or ligase IV we prepared mini whole-cell
extracts (mWCE) from mock-, Ad5- or H5dl1016-infected cells and
used dsDNA cellulose to capture DNA-binding proteins; the bound
fraction. This procedure left proteins that lack afﬁnity for dsDNA in the
unbound fraction. Input, bound and unbound fractions were subject to
Western blot analysis to determine if ligase IV and XRCC4 were
capable of binding DNA. In Fig. 2B we show that in control mWCE
prepared from mock-infected cells, XRCC4 and ligase IV were present
in the input and bound fractions. In Ad5-infected cell mWCE, targeted
degradation of ligase IV resulted in the loss of observable DNA binding
by XRCC4, which was found in the unbound fraction. In mWCE
prepared from H5dl1016-infected cells, the XRCC4 polypeptide was
observed in the input lysate and in the unbound fraction. Similar
results were obtained for ligase IV. In control experiments, we found
that in mWCE prepared frommock-, Ad5- and H5dl1016-infected cells
the Ku heterodimer and DNA-PKcs bound dsDNA equally well (data
not shown), indicating that the dsDNA used in these experiments was
accessible for recognition by DNA-binding proteins. The presence of
DNA-PKcs and Ku in the DNA-bound fraction also indicated that NHEJ
factors with DNA-binding properties similar to those of the ligase IV/
XRCC4 complex are present in the mWCE and retain DNA-binding
activity through the extraction procedure. Taken together, data
presented in Fig. 2 shows E1B 55k-independent disruption of the
ligase IV/XRCC4 protein–protein interaction that was coincident with
loss of DNA binding by ligase IV and XRCC4.
E4 34k forms a complex with DNA ligase IV
Ligase IV is unstable and subject to degradation in the absence of
XRCC4 (Bryans et al. 1999). In extracts prepared from H5dl1016-
Fig. 3. An E4 34k/ligase IV complex in extracts from H5dl1016-infected cells. HeLa cells
were Mock-, Ad5- or H5dl1016-infected and lysed in NP40 lysis buffer 20 h post-
infection. 200 μg of extract was subject to IP with anti-E4 34k antibodies. E4 34k-
containing complexes were resolved on SDS-PAGE, Western transferred and probed for
Ligase IV, XRCC4 and E4 34k. I, 15% of input lysate; IP, immunoprecipitation using anti-
E4 34k antibodies; C, control IP.
Fig. 4. The E4 34k/ligase IV complex observed in extracts from H5dl1016-infected cells
contained Elongins C and B. HeLa cells wereMock-, Ad5- or H5dl1016-infected and lysed
in NP40 lysis buffer 20 h post-infection. (A) 200 μg of extract was subject to IP with
antibodies directed against Elongin B (top) or Elongin C (bottom). Elongin-containing
complexes were resolved by SDS-PAGE, Western transferred and probed for E4 34k. (B)
Complexes containing Elongin B (top) and C (bottom) were isolated as described in (A),
resolved by SDS-PAGE, Western transferred and probed for Ligase IV. I, 15% of input
lysate; IP, immunoprecipitation using anti-Elongin antibodies; C, control IP. M, A and 16;
control IP carried out with lysates from Mock-, Ad5- or H5dl1016-infected cells,
respectively. IP: Elongin B panel was assembled from lanes from a single Western blot.
Fig. 5. The E4 34k/ligase IV complex observed in extracts from H5dl1016-infected cells
contains Cullin5. HeLa cells were Mock-, Ad5- or H5dl1016-infected and lysed in NP40
lysis buffer 20 h post-infection. 200 μg of extract was subject to IP with antibodies
directed against Cullin5. Cul5-containing complexes were resolved by SDS-PAGE,
Western transferred and probed for Ligase IV or E4 34k. I, 15% of input lysate; IP,
immunoprecipitation using anti-Cul5 antibodies; C, control IP.
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quantitatively degraded. These observations suggest that in extracts
prepared from H5dl1016-infected cells, ligase IV may be stabilized
through interaction with other factors of host or viral origin. Previous
observations have shown that targets for the adenoviral E4 34k/E1B
55k ubiquitin E3 ligase can be bound by E4 34k and E1B 55k. Both p53
and Mre11 are targets for the adenoviral ubiquitin E3 ligase and while
p53 can be bound by E4 34k and E1B 55k independently, Mre11 is not
recognized by E4 34k and only bound by E1B 55k. In the absence of E4
34k, ligase IV can form a complex with E1B 55k (Baker et al. 2007). To
determine if ligase IV, like p53, can also form a complex with E4 34k in
the absence of E1B 55k we prepared extracts from mock-, Ad5-, or
H5dl1016-infected cells, immunoprecipitated E4 34k from these
lysates and used Western blot analysis to determine if ligase IV and
E4 34k are part of a new complex.
As shown in Fig. 3, ligase IV and XRCC4 were detected in lysates
frommock-infected cells, which contain no E4 34k. A control E4 34k IP
using mock-infected cell lysates shows no retention of ligase IV or
XRCC4 in the absence of E4 34k. In extracts prepared from Ad5-
infected cells, while degradation precluded detection of ligase IV,
XRCC4 and E4 34k were observed, but did not co-IP. In H5dl1016-
infected cell lysates ligase IV, XRCC4 and E4 34k were all detected and
we observed E4 34k co-IP of ligase IV, but not of XRCC4. Taken
together, these data show that in lysates prepared from cells infected
with H5dl1016, the ligase IV/XRCC4 complex was disrupted and a new
complex E4 34k/ligase IV, which did not contain XRCC4, was observed.
These ﬁndings suggest the intriguing possibility that E4 34k may be
responsible for dissociation of the ligase IV/XRCC4 complex prior to
polyubiquitination of ligase IV.
The E4 34k/ligase IV complex contains the Elongin BC complex
and Cullin5
E4 34k contains three BC box motifs that mediate direct binding of
the Elongin BC complex as part of the E4 34k ubiquitin E3 ligase (E4
34k/Cul5/Rbx1/Elongin BC) (Blanchette et al. 2004). It is thought that
assembly of the E4 34k ubiquitin E3 ligase is a prerequisite to binding
by E1B 55k, which does so through direct contact with E4 34k (Cheng
et al. 2007). Because we have observed E4 34k and ligase IV in the
same complex, we wanted to determine if this complex represented
binding by E4 34k alone, or assembly of the E4 34k ubiquitin E3 ligase.
To do this, we prepared lysates from HeLa cells that had been mock-,
Ad5- or H5dl1016-infected, immunoprecipitated either Elongin B or
Elongin C then used Western blot analysis to determine if E4 34k and
ligase IV co-IP with the Elongins. In extracts prepared from mock-
infected cells, ligase IV was detected in the input lysate, but was not
found to co-IP with the Elongin B or C (Fig. 4). In Ad5-infected cell
extracts, we observed E4 34k in the input lysate and in co-IPs with
both Elongin B and C (Fig. 4). Degradation of ligase IV in Ad5-infected
cells, however, precluded detection of ligase IV. In extracts preparedfrom cells infected with E1B 55k-deﬁcient H5dl1016, we found that
both E4 34k and ligase IV could be detected in the input lysate and that
both proteins co-IP with Elongins B and C (Fig. 4).
E4 34k is thought to mediate selection of Cullin5 by the viral
ubiquitin E3 ligase, possibly through direct protein–protein interac-
tions. While attempts to identify a speciﬁc Cullin5-binding motif in E4
34k were not successful, it is clear that Cullin5 is the predominant
Cullin present in E4 34k-containing complexes (Querido et al. 2001,
Cheng et al. 2007). To determine if the E4 34k-ligase IV complex
contained Cullin5, in addition to the Elongin BC complex, antibodies
against Cullin5 were used to immunoprecipitate Cullin5 from lysates
prepared from mock-, Ad5- or H5dl1016-infected HeLa cells and the
isolated Cullin5-containing complexes were probed for the presence
of E4 34k and ligase IV. As shown in Fig. 5, lysates prepared from
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not interact in the absence of E4 viral proteins. In lysates prepared
from Ad5-infected cells, degradation of ligase IV did not affect
formation or stability of the E4 34k/Cullin5 complex, which was
visualized by co-IP. As previously observed with the Elongin co-IPs,
both ligase IV and E4 34k were detected in the Cullin5 co-IP from
extracts prepared from H5dl1016-infected HeLa cells.
The observation of a ligase IV/E4 34k/Cul5/Elongin BC complex in
the absence of a detectable ligase IV/XRCC4 complex suggests that
assembly of the E4 34k ubiquitin E3 ligase and binding of the
ubiquitination substrate, ligase IV, can take place in the absence of E1B
55k and is coincident with disruption of the ligase IV/XRCC4 complex.
Moreover, these ﬁndings indicate an important role for E4 34k in
dissociation of the ligase IV/XRCC4 complex.Fig. 6. Expression of E4 34k alone is not sufﬁcient to disrupt the ligase IV/XRCC4 complex
in human cells. (A) Expression of Ad5 late proteins in H5dl1011-infected RKO-E4 cells.
RKO and RKO-E4 cells were mock-(M), Ad5-, or H5dl1011-infected (1011). Extracts were
prepared 24 or 48 h post-infection (HPI), resolved by SDS-PAGE, Western transferred
and probed for adenoviral late proteins, E4 34k and XRCC4. Top panel showing late
protein expression was assembled from lanes from a single Western blot. (B) Control
RKO and E4 34k-expressing RKO-E4 cells were lysed in NP40 lysis buffer and 200 μg of
extract was subject to IP with antibodies directed against XRCC4. Immune complexes
were resolved by SDS-PAGE, Western transferred and probed for Ligase IV, XRCC4 and
Actin. I, 7.5% of input lysate; IP, immunoprecipitation using anti-XRCC4 antibodies; C,
control IPs. (C) RKO and RKO-E4 cells were lysed in NP40 lysis buffer and 200 μg of
extract was subject to IP with antibodies directed against E4 34k. Immune complexes
were resolved by SDS-PAGE, Western transferred and probed for E4 34k, Ligase IV,
Elongin B, Elongin C and Actin. I, 10% of input lysate; IP, immunoprecipitation using anti-
E4 34k antibodies; C, control IPs.Expression of E4 34k is not sufﬁcient to disrupt the ligase
IV/XRCC4 complex
Thus far, our data are consistent with the hypothesis that E4 34k
can bind ligase IV, independently of E1B 55k, and that binding of E4
34k to ligase IV results in disruption of the ligase IV/XRCC4 complex.
Because the E4 34k/ligase IV complex observed in H5dl1016-infected
HeLa cells also contained Cullin5 and the Elongin BC complex, we
reasoned that these small proteins may be required for stabilization of
E4 34k/ligase IV interactions and therefore necessary for detection of
the E4 34k/ligase IV complex by co-IP. Additionally, Cullin5, Elongins B
and C, and possibly other human host-cell proteins, might be required
for ligase IV/XRCC4 complex dissociation. To address this possibility
we transiently expressed E4 34k in HeLa cells and found that, despite
detectable levels of E4 34k, the ligase IV/XRCC4 co-IP remained intact
(data not shown). While these results were consistent with the
hypothesis that E4 34k alone is not sufﬁcient to promote dissociation
of the ligase IV/XRCC4 complex, our observations could also be
explained by insufﬁcient transfection efﬁciency.
Radiosensitive RKO-E4 cells were derived from RKO cells and
stably express E4 34k (Hart et al. 2005). Western blot analysis
conﬁrmed expression of E4 34k in RKO-E4 cells and showed that the
amount of E4 34k inmock-infected RKO-E4 cell lysates actually exceed
that observed in lysates prepared from Ad5-infected RKO cells (Fig.
6A). Control experiments showed that when RKO cells were infected
with E4-deletion mutant H5dl1011 (Table 1), the lack of E4 34k
prevented expression of late viral proteins (Fig. 6A). In contrast, the E4
34k expressed in RKO-E4 cells complemented the E4 34k-deﬁciency of
H5dl1011 and late viral proteins were observed 48 h post-infection
(Fig. 6A). We also observed equal expression of XRCC4 by RKO and
RKO-E4 cells, which did not change with Ad5 or H5dl1011 infection.
These data demonstrate expression of functional E4 34k in RKO-E4
cells.
To determine if expression of E4 34k alone is sufﬁcient to disrupt
the ligase IV/XRCC4 complex we used anti-XRCC4 antibodies to IP
XRCC4-containing complexes from lysates prepared from RKO and
RKO-E4 cells. As shown in Fig. 6B, ligase IV was observed in the input
lysate from RKO and RKO-E4 cells and in the XRCC4 co-IP from both
cell lines. Actin, used as a loading control, demonstrated the speciﬁc
retention of XRCC4 and ligase IV by anti-XRCC4 antibodies (Fig. 6B).
Immunoprecipitaiton of E4 34k-containing complexes from lysates
prepared from RKO and RKO-E4 cells show that while E4 34k is
associated with Elongins B and C, ligase IV is not part of that complex
(Fig. 6C). Again, detection of actin serves as both a loading control and
demonstrates the speciﬁcity of the E4 34k IP. Taken together, Figs. 6B
and C show that ligase IV and E4 34k are part of separate multiprotein
complexes.
We conclude from these data that while E4 34k is required for E1B
55k-independent dissociation of the ligase IV/XRCC4 complex,
expression of E4 34k alone in human cells is not sufﬁcient to separate
ligase IV from XRCC4. These ﬁndings suggest the intriguing possibility
that one or more additional factors are required for E4 34k-mediated
dissociation of the ligase IV/XRCC4 complex.
Discussion
During adenoviral infection, host proteins are degraded through
the action of viral proteins E4 34k and E1B 55k. We previously
reported that ligase IV is targeted for degradation during Ad5
infection, and while ligase IV forms a functional complex with
XRCC4 and XLF, protein levels of these ligase IV-binding factors
were unchanged during infection (Baker et al. 2007). Because nuclear
export and translation of host-cell mRNAs are inhibited during
adenovirus infection (Schneider and Mohr 2003, Weitzman and
Ornelles 2005), synthesis of host-cell factors XRCC4 and XLF would
be greatly reduced. The observation of XRCC4 and XLF in the absence
Fig. 7. Schematic representation of E4 34k-mediated ligase IV recognition in adenovirus-infected cells. (A) In cells infected with adenovirus expressing E4 34k, but not E1B 55k,
observation of an E4 34k/Cul5/Elongin BC/ligase IV complex and coincident observation of XRCC4/DNA-PKcs complexes that lack ligase IV indicate that assembly of the E4 34k/Cul5/
Elongin BC ubiquitin E3 ligase and binding to ligase IV results in dissociation of the strong, functional XRCC4-ligase IV direct interaction. Rbx1 (white) is predicted to assemble with
the E4 34k/Cul5/Elongin BC ubiquitin E3 ligase. (B) Model predicts that in the cells infected with adenovirus expressing both E4 34k and E1B 55k, assembly of the E4 34k/E1B 55k/
Cul5/Rbx1/Elongin BC ubiquitin E3 ligase and binding to ligase IV results in ligase IV/XRCC4 dissociation. Polyubiquitination of ligase IV and proteasome-mediated degradation of
ligase IV follows.
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ligase IV complex is disassembled during virus-mediated ligase IV
degradation. Adenovirus-mediated degradation of host-cell factors is
a multi-step process inwhich host-cell target proteins are: i) bound by
viral factors, ii) delivered to the virus-speciﬁc E4 34k/Cul5/Rbx1/
Elongin BC ubiquitin E3 ligase, iii) polyubiquitinated then iv) degraded
by the proteasome. It is plausible that dissociation of the ligase IV
complex might occur at any stage of this complex process. Formation
of new protein–protein contacts might disrupt the ligase IV complex
during recognition of ligase IV by viral target-selection factors or by
binding to the viral ubiquitin E3 ligase. Alteration of ligase IV during
polyubiquitination or degradation could also result in disassembly of
the ligase IV complex.
Here, we provide evidence that dissociation of the ligase IV
complex occurs prior to virus-directed degradation of ligase IV. Using
Ad5 deletion mutant H5dl1016, which does not express E1B 55k but
retains E4 34k expression, we have observed that the functional, direct
interaction between ligase IV and XRCC4 is lost, as is the DNA-binding
activity of this complex. Under these conditions, a ligase IV/E4 34k/
Cul5/Elongin BC complex was evident. We did not observe the high
molecular weight forms of ligase IV that would indicate polyubiqui-
tination. Nor did we observe signiﬁcant degradation of ligase IV. Our
ﬁndings, summarized in Fig. 7A, predict that Rbx1 will be part of the
ligase IV/E4 34k/Cul5/Elongin BC complex and suggest that ligase IV
polyubiquitination and proteasome-mediated degradation follow
ligase IV/XRCC4 complex dissociation. Our data implicate recognition
of ligase IV by viral factors and binding of ligase IV by the viral
ubiquitin E3 ligase as the processes most likely to separate ligase IV
from XRCC4. Our model predicts that in the presence of E1B 55k,
assembly of the E1B 55k/E4 34k/Cul5/Rbx1/Elongin BC ubiquitin E3
ligase causes ligase IV to dissociate from XRCC4 before polyubiquiti-
nation and ligase IV degradation (Fig. 7B).
Host cell target proteins fall into two groups: those recognized only
by E1B 55k (e.g. Mre11) and those that can be independently bound by
E1B 55k and E4 34k (e.g. p53). While p53 can be bound by E4 34k in the
absence of E1B 55k, p53 is not efﬁciently degraded without the
participation of E1B 55k. It is generally thought that E1B 55k mediatesselection of host factors and delivery to the E4 34k ubiquitin E3 ligase.
Wehavepreviously shown thatE1B55k canbind ligase IV in the absence
of E4 34k (Baker et al. 2007). Here, we show that, like p53, ligase IV can
also be recognized by E4 34k and is not efﬁciently degraded in the
absence of E1B 55k. Our ﬁndings suggest an unappreciated E1B-
independent role for E4 34k in selection of some substrates of the viral
ubiquitin E3 ligase prior to ubiquitination and degradation of ligase IV.
Our observations also indicate that structural similarities may exist
between p53 and ligase IV that facilitate recognition by E1B 55k and E4
34k. Investigation of interactions between host and viral factors often
illuminates biologically relevant aspects of host-factor biochemistry. To
gain further insight into the stability of the ligase IV complex, we are
presently working to separate the effects of ligase IV selection from
those of ligase IV binding by the viral ubiquitin E3 ligase to determine
which of these two steps results in dissociation of ligase IV from XRCC4.
We are also working to determine the minimal requirements for
recognition of ligase IV by E4 34k.
Assembly of the E4 34k/Cul5/Rbx1/Elongin BC ubiquitin E3 ligase
has been studied in great detail, and it appears that only E4 34k and
E1B 55k are necessary for degradation of p53 and ligase IV (Querido et
al. 2001, Blanchette et al. 2004, Baker et al. 2007, Cheng et al. 2007). In
attempting to elucidate the minimal requirements for E1B 55k-
independent E4 34k-mediated dissociation of the ligase IV/XRCC4
complex, we have determined that while expression of E4 34k in
human cells resulted in radiosensitivity (Hart et al. 2005), the ligase
IV/XRCC4 complex was intact. These ﬁndings suggest that one or more
additional factors, of host or virus origin, are required for dissociation
of the ligase IV/XRCC4 complex. It has been shown that during
H5dl1016 infection, adenoviral late proteins were not produced at
detectable levels and viral DNA and late mRNA accumulation was
severely impaired (Bridge and Ketner 1990). The observation that
ligase IV and XRCC4 were separated in lysates prepared from
H5dl1016-infected cells allows us to rule out the participation of
adenovirus late proteins in ligase IV/XRCC4 complex dissociation.
Taken together, our data indicate that one, or more, early viral proteins
or virus-induced host proteins may collaborate with E4 34k to
dissociate the ligase IV/XRCC4 complex in the absence of E1B 55k.
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Cell culture and viral infections
HeLa monolayer cell cultures were maintained in Dulbecco's
Modiﬁed Eagle Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 2 mM L-glutamine, 10 μg/mL penicillin, and 10 μg/mL
Streptomycin. Wild type Ad5 and E4 mutants used in these
experiments (H5dl1004, H5dl1013, H5dl1014, H5dl1015 and
H5pm1020; and the E1B 55k deletion mutants H5dl1016 and
H5dl110) have been described previously (Babiss and Ginsberg 1984,
Bridge and Ketner 1989, Bridge and Ketner 1990, Medghalchi et al.
1997). The viruses were propagated on W162 cells, and titered as
plaque forming units (PFU)/mL. For viral infection, culture media was
aspirated and replaced with fresh FBS-free media and the virus was
added at 20 PFU/mL. Virus was allowed to adsorb for 2 h after which
time the media was aspirated and replaced with DMEM containing
10% FBS. The infections were carried out for 20 h post-infection (HPI).
RKO (a generous gift from Steve Balin, JHMI) and RKO-E4 cells (a
generous gift from Constantinos Koumenis, U. Penn.) were cultured in
McCoy's 5A media with 10% FBS. RKO-E4 cultures also contained
100 μg/mL Neomycin Sulfate.
Lysate (extract) preparation and immunoprecipitation
HeLa cells (7×105) were seeded in 35 mm dishes and infected as
described above. Following infection, cells were harvested by
scraping, washed twice with ice cold phosphate buffer saline (PBS)
and lysed in 200 μL of ice cold NP40 lysis buffer (50 mM Tris HCl, pH
8.0, 150 mM NaCl, 2 mM EDTA, 10% glycerol, 1 mM DTT and 1% NP40)
for 20 min at 4 °C by end-over-end mixing. Cellular debris was
removed by centrifugation (16,500 ×g, 10 min, 4 °C). For immuno-
precipitation (IP), 150–200 μg of the extract was treated with the
respective antibody for 2 h at 4 °C with gentle end-over-end mixing.
XRCC4 IPs: rabbit polyclonal XRCC4 (Novus), 1:200 dilution. DNA-
PKcs IPs: rabbit polyclonal anti-DNA-PKcs (Serotec), 1:200 dilution.
Elongin C IPs: anti-Elongin C mAb (BD transduction laboratories),
1:10 dilution. Elongin B IPs: rabbit polyclonal anti-Elongin B (Santa
Cruz), 1:10 dilution. Cullin5 (Cul5) IPs: anti-Cul5 mAb (described
below), 1:100 dilution. For control IP's, FBS was added in place of
antibody. 15% of the treated extract was saved as the input and 20–
30 μl of washed protein-A sepharose beads (GE) was added after
being washed 3 times in lysis buffer. The mixture was then
incubated for 1 h at 4 °C with gentle end-over-end mixing. The
samples were washed 3–8 times in lysis buffer, and resuspended in
2× protein sample buffer.
Preparation of mini whole-cell extracts (mWCE) and DNA binding assay
Mini whole-cell extracts (mWCE) were prepared as previously
described (Smeaton et al. 2007). Brieﬂy, HeLa cells, cultured as
monolayers, were harvested using a cell scraper, washed twice in
twice in PBS, snap frozen on dry ice and stored at −80 °C. Frozen cell
pellets were resuspended in 70–90 μL of hypotonic lysis buffer (10mM
Tris pH 8.0, 1 mM EDTA), incubated on ice for 20 min then subject to
vigorous vortexing for 30 sec. Nuclei were collected by gentle
centrifugation (1300 ×g, 2 min, room temp) and the supernatant
was reserved. Nuclei were resuspended in 35–45 μL of nuclear extract
buffer (25mM Tris pH 8.0, 0.33 M KCl, 1.5 mM EDTA) and incubated on
ice for 20min. The reserved cytoplasmic extract was added back to the
nuclei, cell debris was removed by centrifugation (16,500 ×g, 10 min,
4 °C) and the resulting supernatant was collected as mWCE. For DNA-
binding assays, 20 μL of a 50% native-DNA cellulose (SIGMA) slurry
was added directly to 50 μg of mWCE, incubated for 3 h at room
temperature with turning. DNA cellulose and DNA-bound species
were collected by centrifugation, washed 3 times in 1 mL HEK buffer(20 mM HEPES, pH 7.6, 0.1 M KOAc, 0.5 mM EDTA) and DNA-bound
proteins were eluted with 2× protein sample buffer.
Western blotting and antibodies
For detection of adenoviral late proteins, ligase IV or XRCC4,
samples were heated to 100 °C for 5 min, resolved by SDS-PAGE (8%)
and transferred to 0.45 μM PVDF membrane in the absence of SDS.
Adenoviral late proteins were detected using rabbit polyclonal
antibody (1:2000). XRCC4 was detected with rabbit polyclonal anti-
XRCC4 (Serotec,1:3000). Ligase IV was detectedwith rabbit polyclonal
anti-ligase IV (Serotec, 1:1000). For detection of Elongins B and C,
samples were resolved by 15% SDS-PAGE and transferred to 0.2 μM
PVDF membrane in the absence of SDS. Elongin C was detected with
anti-Elongin C mAb (BD transduction laboratories, 1:500). Elongin B
was detected with rabbit polyclonal anti-Elongin B (Santa Cruz,
1:1000). For detection of E4 34k, samples were not heated prior to
fractionation by SDS-PAGE (15%), after which they were transferred to
PVDF membrane in the presence of 0.037% SDS and E4 34k was
detected using anti-E4 34k rabbit polyclonal antibody raised against
C-terminal octapeptide; 1:1000 dilution. Generation of monoclonal
antibody against human Cullin5 (anti-Cul5 mAb) (Yu et al. 2003):
cDNA encoding 138 amino acids of the N-terminus of Cul5 was
ampliﬁed by PCR with the forward primer 5′-ggatcccatggcgacgtc-
taatctg-3′ and reverse primer 5′-gaattccctaaagctttcgaacaatactg-3′. The
cDNA was inserted into the expression vector pRSETB, and the
sequences were conﬁrmed by direct DNA sequence analysis. E. coli
strain BL21(DE3) (Invitrogen) was used as host to express the Cul5-His
fusion protein. The soluble fusion protein was obtained by IPTG
(0.5 mM) induction at 37 °C for 3 h and puriﬁed using the ProBondTM
puriﬁcation system (Invitrogen) according to manufacturers instruc-
tions. BALB/c mice were immunized with puriﬁed protein to produce
polyclonal antibodies according to conventional procedures: 100 μg of
protein was injected into multiple subcutaneous sites, and mice were
boosted twice at 2-week intervals. Seven days after the last injection,
anti-Cul5 serum was obtained, and the titer and speciﬁcity were
determined by immunoblotting using puriﬁed Cul5-His protein.
Splenic lymphocytes from the mouse with highest anti-Cul5 antibody
titer were fused with murine myeloma cells using polyethylene glycol
1000, hybridomas were selected in medium containing hypoxanthine,
thymidine, and aminopterin, and the media were screened by ELISA
using puriﬁed Cul5-His. One of monoclonal antibody against human
Cul5 was conﬁrmed by immunoblotting using puriﬁed Cul5-His fusion
protein and was used in this study.
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